Filipek-Gorzała Jadwiga, Kwiecińska Patrycja, Szade Agata, Szade Krzysztof
Laboratory of Stem Cell Biology, Faculty of Biochemistry, Biophysics and Biotechnology, Jagiellonian University, Krakow, Poland.
Department of Medical Biotechnology, Faculty of Biochemistry, Biophysics and Biotechnology, Jagiellonian University, Krakow, Poland.
Front Oncol. 2024 Feb 19;14:1308709. doi: 10.3389/fonc.2024.1308709. eCollection 2024.
Hematopoietic stem cells (HSCs) produce all blood cells throughout the life of the organism. However, the high self-renewal and longevity of HSCs predispose them to accumulate mutations. The acquired mutations drive preleukemic clonal hematopoiesis, which is frequent among elderly people. The preleukemic state, although often asymptomatic, increases the risk of blood cancers. Nevertheless, the direct role of preleukemic HSCs is well-evidenced in adult myeloid leukemia (AML), while their contribution to other hematopoietic malignancies remains less understood. Here, we review the evidence supporting the role of preleukemic HSCs in different types of blood cancers, as well as present the alternative models of malignant evolution. Finally, we discuss the clinical importance of preleukemic HSCs in choosing the therapeutic strategies and provide the perspective on further studies on biology of preleukemic HSCs.
造血干细胞（HSCs）在生物体的整个生命过程中产生所有血细胞。然而，造血干细胞的高度自我更新和长寿使其易于积累突变。获得性突变驱动白血病前期克隆性造血，这在老年人中很常见。白血病前期状态虽然通常无症状，但会增加患血癌的风险。尽管如此，白血病前期造血干细胞在成人髓系白血病（AML）中的直接作用已得到充分证明，而它们对其他造血系统恶性肿瘤的贡献仍知之甚少。在这里，我们回顾了支持白血病前期造血干细胞在不同类型血癌中作用的证据，并提出了恶性肿瘤进化的替代模型。最后，我们讨论了白血病前期造血干细胞在选择治疗策略方面的临床重要性，并提供了对白血病前期造血干细胞生物学进一步研究的展望。
